Numerous studies have validated this relationship, and new findings have been made, such as its relationship to alananine transaminase (ALT) serum levels and the full spectrum of NAFLD, including simple steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma, as well as systemic disorders more frequent in these patients, such as cardiovascular risk. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.